Steven Nichtberger, M.D.
President, Chief Executive Officer, and Co-Founder
Dr. Nichtberger has served as Cabaletta’s Chief Executive Officer, President, and Chairman of the Board of Directors since its founding in 2017. Dr. Nichtberger also serves as an adjunct professor at the Wharton School at the University of Pennsylvania. He is also a member of the board of directors of ControlRad, Inc., a medical device company developing and marketing products to reduce radiation exposure associated with medical procedures, a member of the board of directors of the BioAdvance Greenhouse Fund, which provides funding to startup life sciences companies in southeastern Pennsylvania, and a member of the board of governors of Main Line Health, a not-for-profit health system. Dr. Nichtberger is also a venture advisor for the Israel Biotech Fund. Previously, he was the president, chief executive officer, and a member of the board of directors of Tengion, Inc. from 2004 to 2011. Earlier in his career, Dr. Nichtberger served as the head of global marketing for Merck and served in various commercial leadership positions at the company from 1995 to 2003. He has previously served as a member of the boards of directors of the Alliance for Regenerative Medicine (as a founding member), Pennsylvania Bio, (including as chairman), and Biotechnology Industry Organization. He was also a member of the board of overseers for the School of Arts & Sciences at the University of Pennsylvania for over a decade. Dr. Nichtberger received his M.D. from the State University of New York at Buffalo, his B.S. from The Wharton School at the University of Pennsylvania, and his B.A. from the University of Pennsylvania. He completed an internship, residency, and fellowship in the Department of Medicine and the Division of Cardiology of the Mount Sinai Medical Center in New York.
Gwendolyn Binder, Ph.D.
Executive Vice President, Science & Technology
Dr. Binder joined Cabaletta in February 2019 as Executive Vice President, Science, and Technology. She established and leads the preclinical, translational, manufacturing and quality teams. In addition to her position at Cabaletta Bio, she serves on the Board of Directors of Instil Bio, a company developing tumor infiltrating lymphocytes for cancer immunotherapy, and as a member of the Scientific Advisory Board for Immatics, which is a publicly traded company developing engineered T cell immunotherapy for cancer. Prior to joining Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc, where she ultimately led the research team focusing on understanding mechanisms of tumor response and resistance, and translating this understanding to next generation products and clinical study designs. In prior roles, she established and led the translational research group, in addition to the manufacturing and quality teams including oversight of the buildout and commissioning, of an in-house manufacturing facility . Earlier in her career, Dr. Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she progressed multiple IND submissions for novel engineered T-cell therapies in HIV and oncology, including the CD19 CAR IND acquired by Novartis (now Kymriah), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV. Prior to that, she served as the Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg, Maryland where she supported the development of the first clinical lentiviral vector used in humans, for the application of engineered T cell therapy for HIV. Dr. Binder studied viral immunology and translational research at the Johns Hopkins University in Baltimore, Maryland where she earned a Ph.D. in Cellular and Molecular Medicine in 2002. She has authored over 30 publications in the field, including top international journals such as “Science”, and “Nature Medicine”. She is a recognized leader in the biotechnology sector for the translational and clinical advancement of novel T cell therapies for patients with serious diseases.
David J. Chang, M.D., M.P.H.
Chief Medical Officer
Dr. Chang joined Cabaletta in June 2019 as Chief Medical Officer. Previously, he was Senior Vice President and Head, Inflammation, Autoimmunity & Neuroscience, or IA&NS, Global Medicines Development at AstraZeneca Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the late-stage clinical development organization for IA&NS. Prior to AstraZeneca, Dr. Chang served in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. Dr. Chang is an adjunct associate professor in the Division of Rheumatology at the Perelman School of Medicine of the University of Pennsylvania. He received his M.D. from New York University School of Medicine, his M.P.H. from Emory University, and his B.S. from Yale University. Dr. Chang completed his internship and residency in internal medicine at the New York Hospital—Cornell University Medical Center and fellowship in Rheumatology at the Hospital for Special Surgery—Cornell University Medical Center.
Arun Das, M.D.
Executive Director of New Product Planning and Business Development
Dr. Das joined Cabaletta in July 2019 and serves as Executive Director of New Product Planning and Business Development. Before joining our company, Dr. Das was a resident physician in General Pediatrics at the Children’s Hospital of Philadelphia. Previously, he was an investment banking analyst within the healthcare group at Goldman Sachs. In addition, Dr. Das has spent multiple years consulting in business development and operations for several start-ups in the biotechnology space. Dr. Das received his M.D. from Johns Hopkins University School of Medicine and a B.A. and B.S. dual degree from the University of Pennsylvania.
Chief Financial Officer
Mr. Marda joined Cabaletta in January 2019 as Chief Financial Officer. From April 2001 to January 2019, Mr. Marda held positions at Bristol-Myers Squibb, including, most recently, as Vice President, Head of Global Corporate Financial Planning & Analysis, and, from 2014 to 2018, as Head of Finance, R&D Operations and Head of Finance, R&D Portfolio Management and Global Medical. Prior to this, Mr. Marda was Executive Director, U.S. Pharmaceuticals from 2012 to 2014, and Assistant Treasurer, Capital Markets from 2008 to 2012. Mr. Marda received his M.B.A. from the Krannert School of Business of Purdue University and his B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay.
Chief Human Resources Officer
Ms. O’Connor joined Cabaletta in March 2019 as Chief Human Resources Officer. Before joining our company, Ms. O'Connor spent 17 years as a senior executive in Human Resources at Bristol-Myers Squibb, with leadership roles in HR generalist and specialist areas. She has managed global HR teams across many parts of the business, including Research & Development, Commercial, and Corporate Staff. Before joining Bristol-Myers Squibb, Martha spent ten years with Andersen Consulting (Accenture), where she achieved associate partnership as an organization and change management consultant. Martha graduated from Smith College with a bachelor’s degree in Economics and Psychology.
J. Brian Stalter, J.D.
Mr. Stalter joined Cabaletta in September 2019 as General Counsel. Before joining our company, Mr. Stalter served as Vice President & Assistant General Counsel, Business Development at Bristol-Myers Squibb. Previously, Mr. Stalter was Assistant General Counsel, Transactional Practice Group at Bristol-Myers Squibb from September 2005 to July 2016. Earlier in his career, Mr. Stalter was Deputy General Counsel at Medarex, Inc. and Senior Counsel, Licensing at Schering-Plough Corporation. He began his career at Dewey Ballantine LLP in New York. Mr. Stalter received his J.D. from Columbia University and his B.A. in History from the University of Notre Dame.